Managing Hepatitis B and HIV Co-Infection With Treatment Selection and Adherence Counseling

Hepatitis B and HIV co-infection is not uncommon given the overlapping transmission routes of both viruses, and managing this dual diagnosis requires careful treatment planning, David Ha, PharmD, lecturer of medicine at Stanford University School of Medicine, said. Co-infection is clinically significant because HIV-induced immune dysregulation accelerates hepatitis B viral replication, leading to more aggressive liver disease and faster progression to cirrhosis, which is an effect also seen in hepatitis C co-infection. As a result, it is important to treat both infections concurrently rather than prioritizing one over the other.

A critical point in this population is that entecavir should not be used for hepatitis B treatment in patients with HIV co-infection. The limited efficacy data in this setting, combined with cross-exposure risk that can drive resistance to entecavir across both HIV and hepatitis B therapy, makes it an inappropriate choice. Instead, the preferred approach is an HIV treatment regimen that incorporates a tenofovir formulation alongside either lamivudine or emtricitabine, both of which carry activity against hepatitis B and help establish a high-resistance barrier for both infections.

Adherence counseling in this population also requires a nuanced approach. Standard HIV management recommends stopping all antiretroviral drugs simultaneously if a patient becomes nonadherent, in order to minimize the risk of resistance development. However, this guidance conflicts directly with hepatitis B management principles, where abrupt discontinuation can trigger an acute flare of hepatitis B, potentially causing severe and life-threatening liver failure. For patients managing both conditions, the imperative to maintain hepatitis B therapy takes precedence, and clinicians and pharmacists must clearly communicate this distinction to patients to prevent dangerous treatment interruptions.